2560
Views & Citations1560
Likes & Shares
Background: There
is a thesis: CANCER has an often COMPLICATION such as VEIN THROMBOSIS.
Cancer is the second leading cause of death globally, and is
responsible for an estimated 9.6 million deaths in 2018 (The World Health
Organization). Sickness rate of deep vein thromboses is approximately 100 per
100 000 population annually. However, having worked as a vascular surgeon for
several years I was wondering, why I have never detected cancer? So I decided
to analyze 100 cases of morbidity of deep vein thromboses. Thus for the period
2011-2018 there were identified 3 cases of cancer out of 100 cases of deep vein
thromboses. Taking into account a rarity of cancer detection within the group
of patients with deep thromboses, I decided to select a control group of 100
people with cancer who were hospitalized for the planned and urgent surgery to
find out whether they had ever had deep vein thromboses, any deviations in
their coagulograms or whether they had some current problems with the
post-thrombotic complications.
The research
objective:
·
To determine
whether peripheral vein thromboses are the complications of cancer.
·
To detect the
significance of fibrinogen as a biochemical index of risks of thromboses in the
selected groups of the patients.
Methods:
·
Randomized
prospective parallel controlled trial.
·
Randomized
prospective controlled trial.
In Russia there is a program according to which doctors
should carry out the further survey of all the patients with deep vein
thrombosis in order to identify cancer. Based on this program we conduct the
following: X-ray examination of the chest cavity; ultrasound diagnostics of the
abdominal cavity organs, retroperitoneal space and genitourinary system;
fibrogastroduodenoscopy, fibrocolonoscopy, urologist/gynecologist examination;
later, when the cancer is suspected – in-depth follow-up. Moreover, all the
patients should visit a vascular surgeon again in three months and later in 6
months to control the dynamics of vein recanalization and the relevance of the
extension of anticoagulant therapy. Thus we can judge adequately about the
presence or absence of suspicion of any tumor localization. Additionally, 100
cases were analyzed (50 were diagnosed as cancer, 50 were diagnosed as deep
vein thromboses) to detect the significance of fibrinogen as a laboratory index
of risks of thromboses.
Results: Assuming
the equal probability of occurrence of both diseases – cancer and deep vein
thromboses and experimental data, we can easily identify the following
indicators which are commonly used in the evidence-based medical statistics.
I.
Bayes
factor: In our case we
suggest that we will not get even 50% cases of cancer from the group with deep
vein thromboses and that we will not get even 50% cases of deep vein thromboses
in the group with cancer. Thus, the Beyes factor is 0.03. Using Gaussian
approximation P Value=0.01. This result can be considered as the evidence of
significant strength.
QUICK LINKS
- SUBMIT MANUSCRIPT
- RECOMMEND THE JOURNAL
-
SUBSCRIBE FOR ALERTS
RELATED JOURNALS
- Journal of Renal Transplantation Science (ISSN:2640-0847)
- Journal of Clinical Trials and Research (ISSN:2637-7373)
- Journal of Forensic Research and Criminal Investigation (ISSN: 2640-0846)
- Journal of Cell Signaling & Damage-Associated Molecular Patterns
- Journal of Cardiology and Diagnostics Research (ISSN:2639-4634)
- Stem Cell Research and Therapeutics (ISSN:2474-4646)
- Journal of Spine Diseases